Boehringer Ingelheim GmbH - Strategic SWOT Analysis Review

Date: May 3, 2016
Pages: 58
Price:
US$ 125.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: BFFC7371C30EN
Leaflet:

Download PDF Leaflet

Boehringer Ingelheim GmbH - Strategic SWOT Analysis Review
Boehringer Ingelheim GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope
  • Business description – A detailed description of the company’s operations and business divisions. - Corporate strategy – GlobalData’s summarization of the company’s business strategy.
  • SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
Highlights

Boehringer Ingelheim GmbH (Boehringer) is a pharmaceutical company, which carries out research, development, manufacture and sale of pharmaceuticals. The company offers a wide range of products including prescription medicines, consumer health care products, animal health care products and biopharmaceuticals. Its products are used in the treatment of central nervous system disorders, respiratory diseases, cardiovascular diseases, metabolic disorders, cancer, urological and viral conditions, among others. The company focuses on the research, development, manufacture and marketing of new drugs of therapeutic value for human and veterinary medicine. Boehringer operates globally through affiliates and is headquartered in Ingelheim, Germany.

Boehringer Ingelheim GmbH Key Recent Developments

Feb 10, 2016: The European Society of Cardiology announces winners of innovative cardiovascular research grant programme
Dec 22, 2015: Boehringer Ingelheim Invests in Europe: Pharma Company Expands Biopharmaceutical Production at Vienna Site
Dec 21, 2015: Boehringer Ingelheim Selects Medidata Clinical Cloud to Accelerate Innovation in Drug Development
Dec 18, 2015: Boehringer Ingelheim presents strong lung cancer portfolio and long-awaited head-to-head data of afatinib compared to gefitinib at ESMO Asia 2015 Congress
Nov 30, 2015: Lung cancer experts call for improved EGFR mutation testing to allow all eligible NSCLC patients access to personalised treatment

Reasons to Buy
  • Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
  • Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
  • Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
  • Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
Note: Some sections may be missing if data is unavailable for the company.
SECTION 1 - ABOUT THE COMPANY

Boehringer Ingelheim GmbH - Key Facts
Boehringer Ingelheim GmbH - Key Employees
Boehringer Ingelheim GmbH - Key Employee Biographies
Boehringer Ingelheim GmbH - Major Products and Services
Boehringer Ingelheim GmbH - History
Boehringer Ingelheim GmbH - Company Statement
Boehringer Ingelheim GmbH - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Boehringer Ingelheim GmbH - Business Description
Business Description - Animal Health
Animal Health - Overview
Animal Health - Financials
Business Description - Biopharmaceuticals
Biopharmaceuticals - Overview
Biopharmaceuticals - Financials
Business Description - Consumer Health Care
Consumer Health Care - Overview
Consumer Health Care - Financials
Business Description - Industrial Customers and other Sales
Industrial Customers and other Sales - Overview
Industrial Customers and other Sales - Financials
Business Description - Prescription Medicines
Prescription Medicines - Overview
Prescription Medicines - Financials
Boehringer Ingelheim GmbH - Corporate Strategy
Boehringer Ingelheim GmbH - SWOT Analysis
SWOT Analysis - Overview
Boehringer Ingelheim GmbH - Strengths
Strength - Growth in Biopharmaceuticals and Animal Health Divisions
Strength - Delivering Value through Innovation
Strength - Core Segment: Prescription Medicines
Boehringer Ingelheim GmbH - Weaknesses
Weakness - Loss of Exclusivity: Micardis
Weakness - Product Issues
Weakness - Manufacturing Issues at Bedford plant
Boehringer Ingelheim GmbH - Opportunities
Opportunity - Positioned for Growth with Product Launches
Opportunity - Strategic Alliances
Opportunity - Integration of Sanofi’s Merial
Boehringer Ingelheim GmbH - Threats
Threat - Uncertain R&D Outcomes
Threat - Influx of Generics
Threat - Stringent Government Regulations
Boehringer Ingelheim GmbH - Key Competitors

SECTION 3 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
Boehringer Ingelheim GmbH, Medical Equipment, Deals By Year, 2010 to YTD 2016
Boehringer Ingelheim GmbH, Medical Equipment, Deals By Type, 2010 to YTD 2016
Boehringer Ingelheim GmbH, Recent Deals Summary

SECTION 4 – COMPANY’S RECENT DEVELOPMENTS

Feb 10, 2016: The European Society of Cardiology announces winners of innovative cardiovascular research grant programme
Dec 22, 2015: Boehringer Ingelheim Invests in Europe: Pharma Company Expands Biopharmaceutical Production at Vienna Site
Dec 21, 2015: Boehringer Ingelheim Selects Medidata Clinical Cloud to Accelerate Innovation in Drug Development
Dec 18, 2015: Boehringer Ingelheim presents strong lung cancer portfolio and long-awaited head-to-head data of afatinib compared to gefitinib at ESMO Asia 2015 Congress
Nov 30, 2015: Lung cancer experts call for improved EGFR mutation testing to allow all eligible NSCLC patients access to personalised treatment
Nov 17, 2015: NICE Endorsed Tool Launched to Support Patients and Doctors in Shared Decision-Making
Nov 11, 2015: Boehringer Ingelheim will invest 11 billion euros in Research and Development in the next five years to accelerate the discovery of next generation medical breakthroughs
Nov 06, 2015: Change in Board of Managing Directors to ensure continuity and focus on the future
Nov 05, 2015: Ablynx's Partner Boehringer Ingelheim Presented Positive in Vivo Proof-Of-Mechanism Data With Bi-Specific Nanobody at Euro Global Summit On Cancer Therapy
Sep 21, 2015: Boehringer Ingelheim and BioMed X apply crowdsourcing to establish a team of scientists for identifying key epigenetic regulators of COPD

SECTION 5 – APPENDIX

Methodology
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Boehringer Ingelheim GmbH, Key Facts
Boehringer Ingelheim GmbH, Key Employees
Boehringer Ingelheim GmbH, Key Employee Biographies
Boehringer Ingelheim GmbH, Major Products and Services
Boehringer Ingelheim GmbH, History
Boehringer Ingelheim GmbH, Subsidiaries
Boehringer Ingelheim GmbH, Key Competitors
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
Boehringer Ingelheim GmbH, Medical Equipment, Deals By Year, 2010 to YTD 2016
Boehringer Ingelheim GmbH, Medical Equipment, Deals By Type, 2010 to YTD 2016
Boehringer Ingelheim GmbH, Recent Deals Summary

LIST OF FIGURES

Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016
Boehringer Ingelheim GmbH, Medical Equipment, Deals By Year, 2010 to YTD 2016
Boehringer Ingelheim GmbH, Medical Equipment, Deals by Type, 2010 to YTD 2016
Skip to top


OSRAM GmbH - Strategic SWOT Analysis Review US$ 125.00 Feb, 2015 · 37 pages
Oiltanking GmbH - Strategic SWOT Analysis Review US$ 125.00 Feb, 2016 · 30 pages

Ask Your Question

Boehringer Ingelheim GmbH - Strategic SWOT Analysis Review
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: